Comparison of the Risk of Hospitalization and Severe Disease Among Co-circulating Severe Acute Respiratory Syndrome Coronavirus 2 Variants
The Journal of Infectious Diseases · 01.02.2023 · 227 (3) · 332-338
DOI: 10.1093/infdis/jiac385 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Infectious Diseases, online erschienen am 20.09.2022. Verfasst von Camino Trobajo-Sanmartín und 9 weiteren Autor:innen. Beteiligte Einrichtung: Instituto de Salud Pblica de Navarra, Pamplona, Spain. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: Horizon 2020 program of the European Commission, Carlos III Institute of Health with the European Regional Development, Fund.
Abstract (Originalsprache)
Background
We compare the risk of coronavirus disease 2019 (COVID-19) outcomes among co-circulating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants between January 2021 and May 2022 in Navarra, Spain.
Methods
We compared the frequency of hospitalization and severe disease (intensive care unit admission or death) due to COVID-19 among the co-circulating variants. Variants analyzed were non–variants of concern (non-VOCs), Alpha, Delta, Omicron BA.1, and Omicron BA.2. Logistic regression models were used to estimate adjusted odds ratio (aOR).
Results
The Alpha variant had a higher risk of hospitalization (aOR, 1.86 [95% confidence interval {CI}, 1.28–2.71]) and severe disease (aOR, 2.40 [95% CI, 1.31–4.40]) than non-VOCs. The Delta variant did not show a significantly different risk of hospitalization (aOR, 0.73 [95% CI, .40–1.30]) and severe disease (aOR, 3.04 [95% CI, .57–16.22]) compared to the Alpha variant. The Omicron BA.1 significantly reduced both risks relative to the Delta variant (aORs, 0.28 [95% CI, .16–.47] and 0.23 [95% CI, .12–.46], respectively). The Omicron BA.2 reduced the risk of hospitalization compared to BA.1 (aOR, 0.52 [95% CI, .29–.95]).
Conclusions
The Alpha and Delta variants showed an increased risk of hospitalization and severe disease, which decreased considerably with the Omicron BA.1 and BA.2. Surveillance of variants can lead to important differences in severity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Instituto de Salud Pblica de Navarra, Pamplona, Spain.
- CIBER Epidemiologa y Salud Pblica, Madrid, Spain.
- Navarra Institute for Health Research, Pamplona, Spain.
- Clinical Microbiology Department, Hospital Universitario de Navarra, Pamplona, Spain.
ORCID-Profile: Camino Trobajo-Sanmartín
Förderung
- Horizon 2020 program of the European Commission
- Carlos III Institute of Health with the European Regional Development
- Fund
Zitieren
APA
Trobajo-Sanmartín, C., Miqueleiz, A., Guevara, M., Fernández-Huerta, M., Burgui, C., Casado, I., Baigorria, F., Navascués, A., Ezpeleta, C., & Castilla, J. (2023). Comparison of the Risk of Hospitalization and Severe Disease Among Co-circulating Severe Acute Respiratory Syndrome Coronavirus 2 Variants. The Journal of Infectious Diseases, 227(3), 332-338. https://doi.org/10.1093/infdis/jiac385
Vancouver
Trobajo-Sanmartín C, Miqueleiz A, Guevara M, Fernández-Huerta M, Burgui C, Casado I, et al. Comparison of the Risk of Hospitalization and Severe Disease Among Co-circulating Severe Acute Respiratory Syndrome Coronavirus 2 Variants. The Journal of Infectious Diseases. 2023;227(3):332-338. doi:10.1093/infdis/jiac385
BibTeX
@article{TrobajoSanmartn2023,
author = {Trobajo-Sanmartín, Camino and Miqueleiz, Ana and Guevara, Marcela and Fernández-Huerta, Miguel and Burgui, Cristina and Casado, Itziar and Baigorria, Fernando and Navascués, Ana and Ezpeleta, Carmen and Castilla, Jesús},
title = {Comparison of the Risk of Hospitalization and Severe Disease Among Co-circulating Severe Acute Respiratory Syndrome Coronavirus 2 Variants},
journal = {The Journal of Infectious Diseases},
year = {2023},
volume = {227},
number = {3},
pages = {332--338},
doi = {10.1093/infdis/jiac385}
}
EUVIMED